This Viewpoint details the development and regulatory path of aducanumab, a human IgG1 monoclonal antibody to treat Alzheimer disease. More
Infusing blood plasma from people who have recovered from COVID-19 into sick patients looks good on paper. But studies of the treatment haven't found benefits. More
Pharmaceutical company researchers develop a tool to suppress the placebo effect and improve their drug results. More
In this issue of JAMA, Janiaud et al present a meta-analysis of randomized clinical trials (RCTs) of convalescent plasma for the treatment of patients with COVID-19. More
Links between vitamin D deficiencies and coronavirus infections have been seen in studies, but “correlation doesn’t prove causation.” More
This Medical News Quick Uptake examines the debate about a link between vitamin D and COVID-19 risk. More
A key British agency has rejected graded exercise therapy and cognitive behavior therapy as treatments for chronic fatigue syndrome. More
The evidence shows only that the drug might be effective. That once wasn’t enough for F.D.A. approval. More
The new study was completely negative, while an earlier trial of Vascepa, another fish-oil-derived drug, persuaded the FDA to approve it. More
The drugmaker says its mRNA vaccine worked in 90% of patients in its trial, but some observers question how long immunity will last and who will benefit. More